MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3138/canlivj-2026-0003

Медицинская библиотека · Canadian liver journal · 2026

Hepatitis B reactivation in HBsAg-/anti-HB-negative patients diagnosed with hematological malignancy: A case series.

Tharmaratnam Tharmegan, Vakili Sanam Tabataba, Li Daniel, Aleyadeh Wesam, Chen Christine, Wong David, Feld Jordan J

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Hepatitis B virus (HBV) reactivation is a well-recognized complication of immunosuppressive therapy in patients with hematologic malignancies. It usually occurs in those with chronic or resolved HBV infection identified by positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc). Reactivation in patients who test negative for both markers is exceedingly rare and poses a diagnostic challenge.

METHODS

We report on three patients with hematologic malignancies who developed HBV reactivation despite negative baseline serology. Cases were identified and managed at a tertiary liver centre in Canada. Clinical, virologic, and treatment data were reviewed, including HBV serology, viral load, chemotherapy exposure, and outcomes following antiviral therapy.

RESULTS

All three patients originated from HBV-endemic regions and had received potent immunosuppressive regimens, including B cell-depleting agents or hematopoietic stem cell transplantation. Two were completely seronegative (HBsAg-/anti-HBc-/hepatitis B surface antibody [anti-HBs]-negative), and one had isolated anti-HBs positivity that was subsequently lost before reactivation. HBV DNA became detectable months to years after treatment initiation. All patients received antiviral therapy with entecavir or tenofovir, resulting in viral suppression and biochemical recovery.

CONCLUSIONS

This case series highlights a critical limitation of current HBV screening strategies that rely solely on antibody-based testing. Loss of humoral immunity may obscure prior HBV exposure, leading to unrecognized reactivation risk. Clinicians should maintain a high index of suspicion and consider serial ALT and HBsAg monitoring in immunosuppressed patients with humoral (B cell) immune deficiencies, particularly those from HBV-endemic regions.

Для цитирования: Tharmaratnam Tharmegan, Vakili Sanam Tabataba, Li Daniel, Aleyadeh Wesam, Chen Christine, Wong David, Feld Jordan J. Hepatitis B reactivation in HBsAg-/anti-HB-negative patients diagnosed with hematological malignancy: A case series.. Canadian liver journal. 2026. DOI: 10.3138/canlivj-2026-0003.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.